Cytokine storm and colchicine potential role fighting SARS-CoV-2 pneumonia
For some patients with SARS-CoV-2, the worst clinical damage is not caused by the virus itself, but by an overactive inflammatory state. In fact, in some people the immune system goes into overdrive and launches a large-scale assault on the tissue known as cytokine storm. This excessive inflammatory...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2020-04-01
|
| Series: | Italian Journal of Medicine |
| Subjects: | |
| Online Access: | https://www.italjmed.org/index.php/ijm/article/view/1284 |
| _version_ | 1797426909641965568 |
|---|---|
| author | Antonio Vitiello Francesco Ferrara Chiara Pelliccia Giovanni Granata Raffaele La Porta |
| author_facet | Antonio Vitiello Francesco Ferrara Chiara Pelliccia Giovanni Granata Raffaele La Porta |
| author_sort | Antonio Vitiello |
| collection | DOAJ |
| description | For some patients with SARS-CoV-2, the worst clinical damage is not caused by the virus itself, but by an overactive inflammatory state. In fact, in some people the immune system goes into overdrive and launches a large-scale assault on the tissue known as cytokine storm. This excessive inflammatory/immune reaction can damage tissue and eventually kill people. Evidence shows that blocking such cytokine storms can be effective and trials are underway to test drugs that act by reducing cytokine response, such as tocilizumab and sarilumab which bind interleukin 6 (IL-6), or anikinra which is the interleukin 1 receptor antagonist (IL-1). However, other drugs that block the cytokine cascade can also be considered. In this article we describe the scientific and molecular motivation for the use of drugs that act by modulating the hyperactive inflammatory system in severe patients suffering from SARS-CoV-2, considering in particular an old drug that has been in use for many years for other therapeutic indications such as colchicine, and that could be favourable to its use, with low cost and good tolerability. |
| first_indexed | 2024-03-09T08:37:38Z |
| format | Article |
| id | doaj.art-2d9e05bda5b8464f9294d65bd4caadf1 |
| institution | Directory Open Access Journal |
| issn | 1877-9344 1877-9352 |
| language | English |
| last_indexed | 2024-03-09T08:37:38Z |
| publishDate | 2020-04-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Italian Journal of Medicine |
| spelling | doaj.art-2d9e05bda5b8464f9294d65bd4caadf12023-12-02T17:50:06ZengPAGEPress PublicationsItalian Journal of Medicine1877-93441877-93522020-04-0110.4081/itjm.2020.1284Cytokine storm and colchicine potential role fighting SARS-CoV-2 pneumoniaAntonio Vitiello0Francesco Ferrara1Chiara Pelliccia2Giovanni Granata3Raffaele La Porta4Usl Umbria 1, PerugiaUsl Umbria 1, PerugiaUsl Umbria 2, TerniAsl Salerno, SalernoAsur Marche, AnconaFor some patients with SARS-CoV-2, the worst clinical damage is not caused by the virus itself, but by an overactive inflammatory state. In fact, in some people the immune system goes into overdrive and launches a large-scale assault on the tissue known as cytokine storm. This excessive inflammatory/immune reaction can damage tissue and eventually kill people. Evidence shows that blocking such cytokine storms can be effective and trials are underway to test drugs that act by reducing cytokine response, such as tocilizumab and sarilumab which bind interleukin 6 (IL-6), or anikinra which is the interleukin 1 receptor antagonist (IL-1). However, other drugs that block the cytokine cascade can also be considered. In this article we describe the scientific and molecular motivation for the use of drugs that act by modulating the hyperactive inflammatory system in severe patients suffering from SARS-CoV-2, considering in particular an old drug that has been in use for many years for other therapeutic indications such as colchicine, and that could be favourable to its use, with low cost and good tolerability.https://www.italjmed.org/index.php/ijm/article/view/1284SARS-CoV-2COVID-19cytokinecolchicineinfectionimmunology. |
| spellingShingle | Antonio Vitiello Francesco Ferrara Chiara Pelliccia Giovanni Granata Raffaele La Porta Cytokine storm and colchicine potential role fighting SARS-CoV-2 pneumonia Italian Journal of Medicine SARS-CoV-2 COVID-19 cytokine colchicine infection immunology. |
| title | Cytokine storm and colchicine potential role fighting SARS-CoV-2 pneumonia |
| title_full | Cytokine storm and colchicine potential role fighting SARS-CoV-2 pneumonia |
| title_fullStr | Cytokine storm and colchicine potential role fighting SARS-CoV-2 pneumonia |
| title_full_unstemmed | Cytokine storm and colchicine potential role fighting SARS-CoV-2 pneumonia |
| title_short | Cytokine storm and colchicine potential role fighting SARS-CoV-2 pneumonia |
| title_sort | cytokine storm and colchicine potential role fighting sars cov 2 pneumonia |
| topic | SARS-CoV-2 COVID-19 cytokine colchicine infection immunology. |
| url | https://www.italjmed.org/index.php/ijm/article/view/1284 |
| work_keys_str_mv | AT antoniovitiello cytokinestormandcolchicinepotentialrolefightingsarscov2pneumonia AT francescoferrara cytokinestormandcolchicinepotentialrolefightingsarscov2pneumonia AT chiarapelliccia cytokinestormandcolchicinepotentialrolefightingsarscov2pneumonia AT giovannigranata cytokinestormandcolchicinepotentialrolefightingsarscov2pneumonia AT raffaelelaporta cytokinestormandcolchicinepotentialrolefightingsarscov2pneumonia |